Back to top
more

ANI Pharmaceuticals (ANIP)

(Real Time Quote from BATS)

$65.39 USD

65.39
29,859

+0.44 (0.68%)

Updated Apr 26, 2024 03:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kanishka Das headshot

Cybin (CYBN) Begins Phase II Study on Anxiety Drug, Stock Up

by Kanishka Das

Cybin (CYBN) initiates a phase II proof-of-concept study evaluating CYB004 for the treatment of generalized anxiety disorder. The stock rises 7.2%.

Immuneering (IMRX) Plummets 71% in One Week: Here's Why

by Zacks Equity Research

Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.

Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Allogene's (ALLO) fourth-quarter earnings beat estimates, but sales miss the mark. Management expects operating expenses for 2024 to be around $280 million.

Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how ANI Pharmaceuticals (ANIP) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.

Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin

by Zacks Equity Research

New post hoc analysis of data from Lexicon's (LXRX) phase III study shows improvements in glycemic control when treated with sotagliflozin for type 1 diabetes and chronic kidney disease.

Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology

by Zacks Equity Research

Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.

Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study

by Zacks Equity Research

Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.

Why Moderna (MRNA) Stock Price Was Up 9% on Monday

by Zacks Equity Research

Moderna (MRNA) surges amid initiation reports of a phase II/III study on Merck-partnered experimental cancer therapy to treat patients with cutaneous squamous cell carcinoma, a form of skin cancer.

Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82%

by Zacks Equity Research

Following the study's failure, Amylyx (AMLX) is now uncertain whether to pull its orally administered ALS drug from the market. Management has voluntarily decided to pause all promotions of the drug.

MindMed's (MNMD) Anxiety Drug Gets FDA Breakthrough Therapy Tag

by Zacks Equity Research

The FDA bestows a breakthrough therapy designation to MindMed's (MNMD) MM120 for treating generalized anxiety disorder. Shares rise more than 50% on the news.

Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales

by Zacks Equity Research

Emergent (EBS) reports mixed earnings for fourth-quarter 2023. The company signs a forbearance agreement with its lenders, effective till April 2023-end.

Creative Medical (CELZ) Up on Orphan Drug Tag for CELZ-101

by Zacks Equity Research

Creative Medical's (CELZ) CELZ-101 gets FDA's Orphan Drug designation for preventing allograft rejection in type-I diabetes patients undergoing pancreatic islet cell transplantation. Stock rises.

Vanda (VNDA) Falls on FDA's CRL to Hetlioz sNDA for Insomnia

by Zacks Equity Research

Vanda's (VNDA) supplemental new drug application seeking approval for Hetlioz to treat insomnia gets a complete response letter from the FDA.

What Makes ANI Pharmaceuticals (ANIP) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does ANI Pharmaceuticals (ANIP) have what it takes to be a top stock pick for momentum investors? Let's find out.

What's in the Offing for Brainsway (BWAY) in Q4 Earnings?

by Zacks Equity Research

Brainsway's (BWAY) fourth-quarter 2023 performance is likely to have been impacted by the strong momentum across the entire business.

Centene (CNC), Pyx Health Unite to Treat Mental Health Issues

by Zacks Equity Research

Centene (CNC) partners with Pyx Health to address loneliness and mental health issues among the insured.

Wall Street Analysts See ANI (ANIP) as a Buy: Should You Invest?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), ANI (ANIP) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Compared to Estimates, ANI (ANIP) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Humana (HUM) Collaborates With Veda to Enhance Efficiency

by Zacks Equity Research

Humana (HUM) partners with Veda to enhance the quality of provider directories.

Is Cigna Group (CI) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Cigna (CI) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Unveiling ANI (ANIP) Q4 Outlook: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for ANI (ANIP), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.

HCA Healthcare (HCA) Drives Efficiency With New Outpatient Model

by Zacks Equity Research

HCA Healthcare's (HCA) Sarah Cannon Cancer Institute adopts a new outpatient model for CAR T-cell therapy patients.

ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the most recent trading session, ANI Pharmaceuticals (ANIP) closed at $57.63, indicating a -1.27% shift from the previous trading day.